TY - JOUR
TI - Celecoxib for the treatment of atherosclerosis
AU - Papageorgiou, N.
AU - Zacharia, E.
AU - Briasoulis, A.
AU - Charakida, M.
AU - Tousoulis, D.
JO - Expert Opinion on Investigational Drugs
PY - 2016
VL - 25
TODO - 5
SP - 619-633
PB - Taylor and Francis Ltd.
SN - 1354-3784, 1744-7658
TODO - 10.1517/13543784.2016.1161756
TODO - acetylsalicylic acid;  celecoxib;  cyclooxygenase 2;  cyclooxygenase 2 inhibitor;  diclofenac;  etoricoxib;  ibuprofen;  meloxicam;  naproxen;  nonsteroid antiinflammatory agent;  prostacyclin;  rofecoxib;  valdecoxib;  celecoxib;  cyclooxygenase 2 inhibitor, area under the curve;  Article;  atherosclerosis;  cardiovascular mortality;  cardiovascular risk;  cerebrovascular accident;  coronary artery disease;  coronary stenting;  disease course;  drug clearance;  drug efficacy;  drug excretion;  drug half life;  drug mechanism;  drug safety;  drug screening;  gastrointestinal disease;  heart atrium remodeling;  heart failure;  heart infarction;  heart infarction size;  heart protection;  human;  hypertension;  IC50;  inflammation;  kidney disease;  maximum plasma concentration;  mesenchymal stem cell;  monotherapy;  oxidative stress;  percutaneous coronary intervention;  peripheral edema;  pharmacodynamics;  plasma concentration-time curve;  restenosis;  side effect;  thromboembolism;  thrombosis;  volume of distribution;  animal;  atherosclerosis, Animals;  Atherosclerosis;  Celecoxib;  Cyclooxygenase 2 Inhibitors;  Humans
TODO - Introduction: It is widely accepted that inflammation plays a pivotal role in the progression of atherosclerosis. Anti-inflammatory drugs and especially selective cyclooxygenase-2 (COX-2) inhibitors have attracted a keen interest.Areas Covered: In the present drug evaluation article, the authors elucidate the role of celecoxib, a selective COX-2 inhibitor, in the treatment of atherosclerosis. They discuss the atherogenic properties of the COX-2 enzyme. In addition, they address the studies that support an atheroprotective role of celecoxib. Moreover, they provide a review of the literature on the role of COX-2 inhibitors in increasing the rate of major adverse cardiovascular events. Finally, they discuss the emerging evidence that supports celecoxib as an adjuvant or neo-adjuvant therapy to percutaneous coronary intervention (PCI).Expert opinion: Several studies have demonstrated a beneficial effect of celecoxib on the progression of atherosclerosis. Nevertheless, this evidence is mainly derived from preliminary data, while a substantial number of clinical studies have raised concerns regarding the cardiovascular safety of COX-2 inhibitors. Interestingly, recent clinical studies have supported the advantages of short-term celecoxib administration in patients undergoing PCI. However, many more large scale clinical trials are required to assess the long-term safety and efficacy of celecoxib administration in patients with cardiovascular disease. © 2016 Informa UK Limited.
ER -